INKE increases its production capacity with the support of ACCIÓ (Generalitat de Catalunya)
Clifford Chance advises on the financing for Keensight Capital’s acquisition of Inke
Neuraxpharm agrees on the divestment of inhalation API specialist Inke to Keensight Capital
Neuraxpharm announces closing of acquisition of established products from Sanofi
BRUSSELS and DÜSSELDORF, Germany, Jan. 24, 2023 /PRNewswire/ -- Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces the establishment of Neuraxpharm Belgium to cover Belgium and Luxembourg, completing its presence in Benelux as it continues its expansion pathway in Europe.
Neuraxpharm to increase branded business through upcoming acquisition of established products from Sanofi
Are a pharma company's intellectual property rights also a human right? That's the question at the center of a Pfizer controvery in The Dominican Republic.
Inke, a leading global manufacturer of inhalation APIs wholly owned by Neuraxpharm Group, announces it is investing €9 million to increase production ...